Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 2, 2009, Pages 224-227

  Perdigão, João ^a   Macedo, Rita ^b   Malaquias, Ana ^a   Ferreira, Ana ^a   Brum, Laura ^b   Portugal, Isabel ^a,b  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

Author keywords

Antituberculosis drugs; Lisboa family; Mutation analysis; XDR TB

Indexed keywords

BACTERIAL PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; PROTEIN SSR; PROTEIN TLYA; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLONAL VARIATION; GENE CLUSTER; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; MUTATIONAL ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PORTUGAL; TUBERCULOSIS CONTROL; VARIABLE NUMBER OF TANDEM REPEAT;

EID: 77950288031     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp452     Document Type: Article

References (10)

1. World Health Organization. Report of the Meeting of the WHO Global Task Force on XDR-TB: Geneva, Switzerland, 9-10 October 2006. WHO Publication No. WHO/HTM/TB/2007.375. Geneva: World Health Organization, 2007.
2. Francis J. Curry National Tuberculosis Center and California Department of Public Health. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 2nd edn. San Francisco, CA: Francis J. Curry National Tuberculosis Center, 2008.
3. LoBue P. Extensively drug-resistant tuberculosis. Curr Opin Infect Dis 2009; 22: 167-73.
4. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis Surveillance in Europe 2007. Stockholm: European Centre for Disease Prevention and Control, 2009.
5. Portugal I, Covas MJ, Brum L et al. Outbreak of multiple drug-resistant tuberculosis in Lisbon: detection by restriction fragment length polymorphism analysis. Int J Tuberc Lung Dis 1999; 3: 207-13.
6. Perdigao J, Macedo R, Joao I et al. Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb Drug Resist 2008; 14: 133-43.
7. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 3192-7.
8. Jugheli L, Bzekalava N, de Rijk P et al. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 2009; 53: 5064-8.
9. Maus CE, Plikaytis BB, Shinnick TM. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 571-7.
10. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47: 1767-72.